How to Order KENGREAL® (cangrelor)
Ordering KENGREAL is just a few steps away.
How is KENGREAL supplied?
KENGREAL is supplied as a sterile, lyophilized powder in single-use, 10-mL vials, each containing 50 mg of KENGREAL.1
10 count of 10-mL vials containing 50 mg of KENGREAL
NDC No.
Carton weight
Carton dimensions
NDC 10122-620-10
5.9 oz
L x W X H: 5.9 x 2.5 x 2.5 in
- NDC 10122-620-01: 10-mL vial containing 50 mg of KENGREAL
Ordering KENGREAL
- KENGREAL is a wholesaler-stocked product; please use standard ordering procedure through your wholesaler
- If product is not available at your wholesaler, your wholesaler can easily coordinate a drop shipment via Next-Day Saver from a Chiesi USA distribution provider
Pricing varies and is subject to change. Consult your wholesaler for up-to-date pricing.
Program
Options
Group Purchasing Organization
Apexus
Federal Supply Schedule
340B
Storing KENGREAL
KENGREAL vials should be stored at USP Controlled Room Temperature (20°C to 25°C; 68°F to 77°F) with excursions between 15°C and 30°C (59°F and 86°F) permitted. KENGREAL can be stocked in the cath lab.1
Stock KENGREAL
USP=United States Pharmacopeia.
Important Safety Information
KENGREAL® (cangrelor) for Injection is contraindicated in patients with significant active bleeding.
KENGREAL® is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to cangrelor or any component of the product.
Drugs that inhibit platelet P2Y12 function, including KENGREAL®, increase the risk of bleeding. In CHAMPION PHOENIX, bleeding events of all severities were more common with KENGREAL® than with clopidogrel. Bleeding complications with KENGREAL® were consistent across a variety of clinically important subgroups. Once KENGREAL® is discontinued, there is no antiplatelet effect after an hour.
The most common adverse reaction is bleeding.
Please see Full Prescribing Information.
Indication
KENGREAL® (cangrelor) for Injection is a P2Y12 platelet inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.
Reference: 1. KENGREAL® (cangrelor) Prescribing Information. 2022.